Showing 15 posts of 69 posts found.

Otsuka and Lundbeck gain FDA approval for supplemental New Drug Application for dementia drug

May 11, 2023
Medical Communications FDA, Lundbeck, Neurology, Otsuka Pharmaceuticals, alzheimer's disease, dementia

Japan-based healthcare company Otsuka Pharmaceutical and Danish pharma company Lundbeck have announced that the US Food and Drug Administration (FDA) …

Lundbeck to restructure R&D, shedding up to 160 jobs

June 10, 2020
Manufacturing and Production, Research and Development Lundbeck, pharma, staff cuts

Danish neuroscience specialist Lundbeck has announced it will be implementing a restructure of its Research & Development operations – a …

Lundbeck’s Vyepti secures US approval for migraine prevention

February 24, 2020
Sales and Marketing FDA, Lundbeck, Vyepti, migraine, pharma

Lundbeck’s Vyepti (eptinezumab-jjmr) has secured approval from the FDA, it has emerged, for the prevention of migraine in adult patients. …


Lundbeck and Takeda’s depression drug approved in Japan

September 20, 2019
Medical Communications, Sales and Marketing Japan, Lundbeck, Takeda, major depressive disorder, pharma

Takeda and Lundbeck have announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has chosen to authorise their drug …

Lundbeck acquires Alder in $2bn migraine treatment move

September 16, 2019
Sales and Marketing Alder, Lundbeck, eptinezumab, migraine

Lundbeck is to buy Alder Biopharmaceuticals for $2 billion enhancing its leading portfolio of brain disease therapies through the acquisition …

Lundbeck acquire Abide Therapeutics in deal worth $400 million

May 7, 2019
Manufacturing and Production, Sales and Marketing Abide Therapeutics, Lundbeck, endocannabinoid system, neuropathic pain, tourette's

Danish firm Lundbeck has agreed to acquire San Diego-based biotech Abide Therapeutics as part of a deal worth $400 million. …

23andMe to offer genetic reports on diabetes

March 11, 2019
Sales and Marketing 23andME, Genentech, GlaxoSmithKline, Lundbeck, diabetes, genetics, genomics

Personal genomics company, 23andMe will offer customers information on the likelihood that they are genetically predisposed to developing type 2 …

Lundbeck and Otsuka’s bipolar treatment fails Phase 3 trials due to unexpected placebo effect

February 15, 2019
Medical Communications CNS, Lundbeck, Otsuka, Rexulti, bipolar disorder, mental health

Lundbeck and Otsuka’s treatment for bipolar disorder, Rexulti, failed to achieve its primary endpoint in two separate Phase 3 trials. …


Top Ten most popular articles on this week

March 23, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Canada, Celgene, Lundbeck, Marijuana, Novartis, Roche, Vertex, brexit, cannabis, multiple sclerosis, neuroscience, pharma

As me move startlingly quickly towards Easter, it’s time for another Top Ten rundown. This week, Celgene surprised the industry …

Lundbeck takes risk on Parkinson’s treatment, €905m on table

March 19, 2018
Sales and Marketing Lundbeck, Parkinson's, biotech, drugs, pharma, pharmaceutical

CNS’ treatments are notoriously risky, especially those that are still at an early stage; however, Lundbeck has decided to take …


Teva finally announces successful CEO appointment

September 11, 2017
Medical Communications, Sales and Marketing Lundbeck, Teva, biotech, drugs, pharma, pharmaceutical

Teva has announced that its protracted search for a new CEO has finally come to end, as it revealed the …

Two Phase 3 failures put nail in the coffin for Lundbeck Alzheimer’s drug

February 9, 2017
Research and Development, Sales and Marketing Alzheimer's, Lundbeck, idalopirdine

Danish pharma firm Lundbeck has announced the failure of two Phase 3 trials investigating its experimental Alzheimer’s treatment idalopirdine; the …


Alzheimer’s drug failure sends Lundbeck’s shares crashing

September 23, 2016
Medical Communications, Research and Development Alzheimer's, Lundbeck, cultural failings

Lundbeck’s experimental idalopirdine has failed to meet its primary endpoint in its first Phase III trial in the treatment of …

Lundbeck, Otsuka’s trial Alzheimer’s disease drug gets US FDA fast track designation

July 8, 2016
Medical Communications, Research and Development Alzheimer's disease, Lundbeck, Otsuka, US FDA, drug development, drug trial, fast track designation

H. Lundbeck A/S (CPH: LUN) and Otsuka Pharmaceutical said the US Food and Drug Administration (FDA) have granted Fast Track …


Weekly Movers: Teva, Midatech, Allergan…

May 16, 2016
Research and Development, Sales and Marketing Allergan, Ariad Pharmaceuticals, Lundbeck, Midatech Pharma, Stock, Teva Pharmaceutical, markets

We have hit the tail end of the earnings season and the near last batch of movers follow result pronouncements …

Latest content